Those criteria include, besides family history, the occurrence of second malignancies, specific tumour entities with a high rate of cancer predisposition (e.g., adrenocortical carcinoma for TP53), excessive toxicity and other specific features as well as paediatric patients with rare or adult-type tumours [2, 3]. Here, TP53 is linked to neoplasm.